What is the role of mesylate (Brisdelle) in the treatment of menopausal symptoms?

Updated: Jun 06, 2018
  • Author: PonJola Coney, MD; Chief Editor: Richard Scott Lucidi, MD, FACOG  more...
  • Print


In June 2013, the FDA approved paroxetine mesylate (Brisdelle) as the first nonhormonal therapy for vasomotor symptoms (VMS) (hot flashes) associated with menopause. [7, 8]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!